Molecular Biomedicine, launched in 2020, is a peer-reviewed, open access journal published annually. It is a collaborative venture between the globally renowned scientific publishing company Springer Nature and the Sichuan Association for the Promotion of International Medical Exchange. This journal is dedicated to publishing high-quality research in the field of biomedicine from a molecular perspective, encompassing both fundamental and clinical studies.

Focusing on the mechanisms of human disease, as well as advancements in prevention, diagnosis, and treatment, Molecular Biomedicine aims to become a leading international academic journal with a significant impact in the biomedicine sector. The journal's commitment to open access ensures that its content is widely accessible, fostering global exchange of scientific knowledge and accelerating the dissemination of breakthroughs in molecular medicine.By embracing innovative research methodologies and interdisciplinary approaches, Molecular Biomedicine is positioned to contribute to the advancement of medical science, offering insights that could potentially lead to improved healthcare outcomes. The journal's editorial board, composed of experts from around the world, ensures that the published work meets the highest standards of scientific rigor and integrity, solidifying its reputation as a trusted source of information in the scientific community.